PCN124 COST-UTILITY ANALYSIS OF DASATINIB IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA (CML) ON CHRONIC (CP), ACCELERATED (AP) AND BLAST (BP) PHASES IN BRAZIL
Oct 1, 2009, 00:00
10.1016/S1098-3015(10)74375-8
https://www.valueinhealthjournal.com/article/S1098-3015(10)74375-8/fulltext
Title :
PCN124 COST-UTILITY ANALYSIS OF DASATINIB IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA (CML) ON CHRONIC (CP), ACCELERATED (AP) AND BLAST (BP) PHASES IN BRAZIL
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)74375-8&doi=10.1016/S1098-3015(10)74375-8
First page :
Section Title :
Open access? :
No
Section Order :
301